Immuron Ltd
IMM-529
Clostridioides difficile infection
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for IMM-529 in Clostridioides difficile infection are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“October 2025 anticipated top line results”